part time job

IASLC World Conference on Lung Cancer–Press Briefing Summary from Sunday, September 8th

BARCELONA, Spain, Sept. 8, 2019 /PRNewswire/ — A clinical trial testing the toxicity of a KRAS inhibitor demonstrated early promising antitumor activity and few adverse side effects in patients with advanced non-small cell lung cancer harboring KRAS G12C mutation, according to Ramaswamy…